Lon Cardon - 29 May 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role: Director
Signature: /s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol: MIRM
Transactions as of: 29 May 2025
Net transactions value: $0
Form type: 4
Filing time: 02 Jun 2025, 19:34:29 UTC
Previous filing: 07 Jun 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cardon Lon	Director	C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY	/s/ Judit Ryvkin, Attorney-in-Fact	02 Jun 2025	0001854337

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MIRM	Common Stock	Options Exercise		+5,703			5,703	29 May 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MIRM	Restricted Stock Units	Options Exercise	$0	-5,703	-100%	$0.000000	0	29 May 2025	Common Stock	5,703		Direct	F1, F2
transaction	MIRM	Stock Option (right to buy)	Award	$0	+6,268		$0.000000	6,268	29 May 2025	Common Stock	6,268	$44.00	Direct	F3
transaction	MIRM	Restricted Stock Units	Award	$0	+3,977		$0.000000	3,977	29 May 2025	Common Stock	3,977		Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
F2	The restricted stock unit vests on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2025 annual stockholder meeting.
F3	The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting.
F4	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting.